Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Isconova to develop human vaccines with animal technology

This article was originally published in Scrip

Executive Summary

Isconova has secured SKK30 million ($5.0 million) to develop human vaccine adjuvants and increase vaccine production and marketing. The cash will help the Swedish firm diversify its pipeline which largely consists of marketed animal vaccines. The company's vaccine adjuvant technology, ISCOM, makes longer-lasting and more protective vaccines. The technology is already established in horse vaccines throughout Europe and Isconova will now explore ISCOM in humans. The investment was provided by InnovationsKapital and other undisclosed private investors.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts